Look up one drug

Sandoz Adapalene/ Benzoyl Peroxide · DIN 02489007 Manufacturer: Sandoz Canada Inc.; listing date 2019-11-29 Health Canada: Marketed since 2021-06-21 · brand SANDOZ ADAPALENE / BENZOYL PEROXIDE · ATC D10AD53 ADAPALENE, COMBINATIONS, D10AD53 ADAPALENE, COMBINATIONS · form Gel · route Topical · ingredients ADAPALENE 0.1 %/W/W, BENZOYL PEROXIDE 2.5 %/W/W · company Sandoz canada incorporated · schedule Prescription

DIN 02489007: Sandoz Adapalene/ Benzoyl Peroxide Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 842800058; group id 852; item number 2070; lccId None; manufacturer id SDZ Source form: Top Gel; strength: 0.1%w/w & 2.5%w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2718; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02489007 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97906

Interchangeable products

TactuPump · DIN 02365871 · not recorded Taro-Adapalene/Benzoyl Peroxide · DIN 02456923 · not recorded

Shortage status: resolved shortage (ended 2025-09-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489007

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

TactuPump · DIN 02365871 Manufacturer: Galderma Canada Inc; listing date 2019-11-29 Health Canada: Marketed since 2014-06-02 · brand TACTUPUMP · ATC D10AD53 ADAPALENE, COMBINATIONS, D10AD53 ADAPALENE, COMBINATIONS · form Gel · route Topical · ingredients BENZOYL PEROXIDE 2.5 %/W/W, ADAPALENE 0.1 %/W/W · company Galderma canada inc. · schedule Prescription

DIN 02365871: TactuPump Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 842800058; group id 852; item number 2070; lccId None; manufacturer id GAC Source form: Top Gel; strength: 0.1%w/w & 2.5%w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02365871 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85075

Interchangeable products

Sandoz Adapalene/ Benzoyl Peroxide · DIN 02489007 · not recorded Taro-Adapalene/Benzoyl Peroxide · DIN 02456923 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02365871

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Adapalene/Benzoyl Peroxide · DIN 02456923 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2019-11-29 Health Canada: Marketed since 2019-10-01 · brand TARO-ADAPALENE/BENZOYL PEROXIDE · ATC D10AD53 ADAPALENE, COMBINATIONS, D10AD53 ADAPALENE, COMBINATIONS · form Gel · route Topical · ingredients ADAPALENE 0.1 %/W/W, BENZOYL PEROXIDE 2.5 %/W/W · company Taro pharmaceuticals inc · schedule Prescription

DIN 02456923: Taro-Adapalene/Benzoyl Peroxide Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 842800058; group id 852; item number 2070; lccId None; manufacturer id TAR Source form: Top Gel; strength: 0.1%w/w & 2.5%w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2719; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456923 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94404

Interchangeable products

Sandoz Adapalene/ Benzoyl Peroxide · DIN 02489007 · not recorded TactuPump · DIN 02365871 · not recorded

Shortage status: resolved shortage (ended 2025-08-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456923

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Adapalene/Benzoyl Peroxide · DIN 02517205 Manufacturer: Sandoz Canada Inc.; listing date 2022-01-31 Health Canada: Marketed since 2022-01-26 · brand SANDOZ ADAPALENE / BENZOYL PEROXIDE FORTE · ATC D10AD53 ADAPALENE, COMBINATIONS, D10AD53 ADAPALENE, COMBINATIONS · form Gel · route Topical · ingredients BENZOYL PEROXIDE 2.5 %/W/W, ADAPALENE 0.3 %/W/W · company Sandoz canada incorporated · schedule Prescription

DIN 02517205: Sandoz Adapalene/Benzoyl Peroxide Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 843600106; group id 855; item number 2075; lccId None; manufacturer id SDZ Source form: Top Gel; strength: 0.3% w/w & 2.5% w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.1576; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02517205 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100638

Interchangeable products

TactuPump Forte · DIN 02446235 · not recorded Taro-Adapalene/Benzoyl Peroxide Forte · DIN 02505053 · not recorded

Shortage status: resolved shortage (ended 2024-11-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517205

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

TactuPump Forte · DIN 02446235 Manufacturer: Galderma Canada Inc; listing date 2022-01-31 Health Canada: Marketed since 2016-01-04 · brand TACTUPUMP FORTE · ATC D10AD53 ADAPALENE, COMBINATIONS, D10AD53 ADAPALENE, COMBINATIONS · form Gel · route Topical · ingredients ADAPALENE 0.3 %/W/W, BENZOYL PEROXIDE 2.5 %/W/W · company Galderma canada inc. · schedule Prescription

DIN 02446235: TactuPump Forte Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 843600106; group id 855; item number 2075; lccId None; manufacturer id GAC Source form: Top Gel; strength: 0.3% w/w & 2.5% w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02446235 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93152

Interchangeable products

Sandoz Adapalene/Benzoyl Peroxide · DIN 02517205 · not recorded Taro-Adapalene/Benzoyl Peroxide Forte · DIN 02505053 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02446235

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Adapalene/Benzoyl Peroxide Forte · DIN 02505053 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2022-02-28 Health Canada: Marketed since 2022-01-24 · brand TARO-ADAPALENE/BENZOYL PEROXIDE FORTE · ATC D10AD53 ADAPALENE, COMBINATIONS, D10AD53 ADAPALENE, COMBINATIONS · form Gel · route Topical · ingredients ADAPALENE 0.3 %/W/W, BENZOYL PEROXIDE 2.5 %/W/W · company Taro pharmaceuticals inc · schedule Prescription

DIN 02505053: Taro-Adapalene/Benzoyl Peroxide Forte Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 843600106; group id 855; item number 2075; lccId None; manufacturer id TAR Source form: Top Gel; strength: 0.3% w/w & 2.5% w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.1577; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02505053 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99442

Interchangeable products

Sandoz Adapalene/Benzoyl Peroxide · DIN 02517205 · not recorded TactuPump Forte · DIN 02446235 · not recorded

Shortage status: resolved shortage (ended 2025-02-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02505053

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 724 For the treatment of acne vulgaris in patients 12 years of age and older. Coverage limit: LU Authorization Period: 1 year

Cabtreo · DIN 02550423 Manufacturer: Bausch Health Canada Inc.; listing date 2025-06-30 Health Canada: Marketed since 2024-10-07 · brand CABTREO · ATC D10AF51 CLINDAMYCIN, COMBINATIONS · form Gel · route Topical · ingredients ADAPALENE 0.15 %/W/W, BENZOYL PEROXIDE 3.1 %/W/W, CLINDAMYCIN PHOSPHATE 1.2 %/W/W · company Bausch health, canada inc. · schedule Prescription

DIN 02550423: Cabtreo Raw flags: sec12=Y, sec3=Y Item: 840404031; group id 810; item number 1988; lccId 00411; manufacturer id BHC Source form: Top Gel Pump; strength: 1.2% w/w & 0.15% w/w & 3.1% w/w Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.0074; ministry $3.0074 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550423 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103924

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02550423

Shortage record checked 2026-09-13T08:10:21.292534+00:00